| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Neuropeptide VF (124-131) targets the NPFF1 receptor as an agonist. It inhibits gonadotropin secretion by inhibiting Ca2+ mobilization. The peptide has an IC₅0 of 0.7 nM for inhibiting forskolin-induced cAMP accumulation.
|
|---|---|
| ln Vitro |
RFRP-3 has an IC50 of 0.7 nM, which is an efficient inhibitor of forskolin-induced cAMP production[1]. A Scatchard plot analysis revealed that CHO cells expressing rat OT7T022 exhibited a single class of high-affinity binding sites for 125I-labeled hRFRP-3, with Bmax and Kd values of 1.3pM and 0.19nM, respectively. In cells transfected with the novel orphan 7TMR OT7T022, RFRP-3 preferentially activates the cells and binds to OT7T022 as a specific ligand with high affinity (Kd= 0.19 nM) [1]. When taken alone, RFRP-3 (10-8 to 10-14M) has little effect on LH and FSH levels; however, when paired with GnRH, LH and FSH secretion is considerably suppressed [1].
In vitro, Neuropeptide VF (124-131) acts as a potent inhibitor of gonadotropin secretion by inhibiting Ca2+ mobilization. It is an NPFF1 receptor agonist and inhibits forskolin-induced cAMP accumulation with an IC₅0 of 0.7 nM. |
| ln Vivo |
In vivo, Neuropeptide VF (124-131) inhibits gonadotropin secretion. As a GnIH homolog, it plays a role in the regulation of the reproductive axis. The peptide may be used to study the negative regulation of gonadotropin secretion and reproductive function.
|
| Enzyme Assay |
Receptor binding assays for Neuropeptide VF (124-131) use membrane preparations from cells expressing the NPFF1 receptor. Radiolabeled ligand is incubated with varying concentrations of the test peptide, and binding affinity is determined by competition binding curves.
|
| Cell Assay |
Cellular assays for Neuropeptide VF (124-131) typically use cell lines expressing the NPFF1 receptor. Cells are treated with the peptide, and cAMP accumulation or Ca2+ mobilization is measured to assess receptor activation and inhibition.
|
| Animal Protocol |
In vivo studies with Neuropeptide VF (124-131) are conducted in rodent models. The peptide is typically administered via intracerebroventricular or intravenous injection. Serum LH and FSH levels are measured to assess the inhibition of gonadotropin secretion.
|
| ADME/Pharmacokinetics |
As an 8-amino acid peptide, Neuropeptide VF (124-131) is expected to have a short half-life due to proteolytic degradation. The peptide should be stored as a solid powder at -20degC. Standard peptide handling and storage procedures apply.
|
| Toxicity/Toxicokinetics |
Toxicity data for Neuropeptide VF (124-131) are limited. Peptide research compounds are generally considered to have low toxicity at pharmacological doses. Standard safety precautions for laboratory handling of peptides should be followed.
|
| References | |
| Additional Infomation |
H-Val-pro-asn-leu-pro-gln-arg-phe-NH2 is a peptide.
Neuropeptide VF (124-131) is a research-use peptide and is not approved for therapeutic applications. It is also known as RFRP-3 (human). The peptide is used to study the regulation of gonadotropin secretion and reproductive endocrinology. It is available from multiple research suppliers. |
| Molecular Formula |
C45H72N14O10
|
|---|---|
| Molecular Weight |
969.14100
|
| Exact Mass |
968.556
|
| CAS # |
311309-27-0
|
| Related CAS # |
RFRP-3(human) TFA
|
| PubChem CID |
71451611
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.376
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
27
|
| Heavy Atom Count |
69
|
| Complexity |
1870
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(C)C)N
|
| InChi Key |
JFZCLMZUABKABL-GVCDGELBSA-N
|
| InChi Code |
InChI=1S/C45H72N14O10/c1-24(2)21-31(57-40(65)30(23-35(47)61)56-42(67)33-15-10-20-59(33)44(69)36(48)25(3)4)43(68)58-19-9-14-32(58)41(66)54-28(16-17-34(46)60)39(64)53-27(13-8-18-52-45(50)51)38(63)55-29(37(49)62)22-26-11-6-5-7-12-26/h5-7,11-12,24-25,27-33,36H,8-10,13-23,48H2,1-4H3,(H2,46,60)(H2,47,61)(H2,49,62)(H,53,64)(H,54,66)(H,55,63)(H,56,67)(H,57,65)(H4,50,51,52)/t27-,28-,29-,30-,31-,32-,33-,36-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~103.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0318 mL | 5.1592 mL | 10.3184 mL | |
| 5 mM | 0.2064 mL | 1.0318 mL | 2.0637 mL | |
| 10 mM | 0.1032 mL | 0.5159 mL | 1.0318 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
